| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute on Drug Abuse (NIDA) |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000344 |
Purpose
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment.
| Condition | Intervention | Phase |
|
Opioid-Related Disorders |
Drug: Buprenorphine/naloxone |
Phase II |
| Drug Information available for: | Naloxone Naloxone hydrochloride Buprenorphine Buprenorphine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind |
| Official Title: | Trial of Buprenorphine/Naloxone for Treatment of Opiate Dependence |
Eligibility
| Ages Eligible for Study: | 21 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
M/F ages 21-50. Meet DSM-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
Contacts and Locations| United States, California | |||||
| Friends Research Institute | |||||
| Los Angeles, California, United States, 90025 | |||||
| Principal Investigator: | Walter Ling, M.D. | Friends Research Institute, Inc. |
More Information
| Study ID Numbers: | NIDA-3-0010-9, Y01-3-0010-9 |
| First Received: | September 20, 1999 |
| Last Updated: | August 26, 2008 |
| ClinicalTrials.gov Identifier: | NCT00000344 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
